Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Mar;2(3):211-3.
doi: 10.1158/2159-8290.CD-12-0037.

Anti-VEGF therapy revived by c-Met inhibition, but is c-Met the answer?

Kristi D Lynn  1 , Rolf A Brekken
Affiliations
Comment

Anti-VEGF therapy revived by c-Met inhibition, but is c-Met the answer?

Kristi D Lynn et al. Cancer Discov. 2012 Mar.

Abstract

A new study by Sennino and colleagues demonstrates that selective VEGF inhibition via the use of an anti-VEGF antibody is sufficient to increase invasion and metastasis in a c-Met-dependent manner. Anti-VEGF therapy induced tumor hypoxia, hypoxia-inducible factor 1α, and c-Met activation in the RIP-Tag2 model of neuroendocrine pancreatic cancer. Selective c-Met inhibition was sufficient to block these effects, providing a potential mechanism for and solution to overcome increased invasion in the face of anti-VEGF therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

R.A. Brekken received a commercial research grant from Affitech A/S and Imclone Systems and consulted for Peregrine Pharmaceuticals. No potential conflicts of interest were disclosed by the other author.

Comment on

References

    1. Ferrara N. Vascular endothelial growth factor: basic science clinical progress. Endocr Rev. 2004;25:581–611. - PubMed
    1. Tanne JH. FDA cancels approval for bevacizumab in advanced breast cancer. BMJ. 2011;343:d7684. - PubMed
    1. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232–9. - PMC - PubMed
    1. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220–31. - PMC - PubMed
    1. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007;104:17069–74. - PMC - PubMed

MeSH terms